Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey

被引：18
作者：
Lip, Gregory Y. H. [1 ]
Bongiorni, Maria Grazia [2 ]
Dobreanu, Dan [3 ]
Lewalter, Thorsten [4 ]
Hastrup Svendsen, Jesper [5 ,6 ]
Blomstrom-Lundqvist, Carina [7 ]
机构：
[1] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp Birmingham, Birmingham B18 7DH, W Midlands, England
[2] Univ Hosp Pisa, Cardiol Dept 2, Pisa, Italy
[3] Univ Med & Pharm, Dept Cardiol, Ctr Cardiovasc Dis & Transplant, Targu Mures, Romania
[4] Isar Heart Ctr Munich, Munich, Germany
[5] Univ Copenhagen, Rigshosp, Ctr Heart, Dept Cardiol, DK-2100 Copenhagen, Denmark
[6] Danish Natl Res Fdn, Ctr Cardiac Arrhythmia, Copenhagen, Denmark
[7] Uppsala Univ, Dept Cardiol, Inst Med Sci, Uppsala, Sweden
来源：
EUROPACE | 2013年 / 15卷 / 10期
关键词：
Atrial fibrillation; Anticoagulation; Guidelines; Warfarin; New oral anticoagulants; Apixaban; Dabigatran; Rivaroxaban; Stroke; EP wire; EHRA survey; ADHERENT ANTITHROMBOTIC TREATMENT; NET CLINICAL BENEFIT; DABIGATRAN ETEXILATE; RANDOMIZED EVALUATION; RISK STRATIFICATION; CONSENSUS DOCUMENT; CATHETER ABLATION; SYSTEMIC EMBOLISM; MODELING ANALYSIS; THERAPY;
D O I：
10.1093/europace/eut292
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The purpose of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke prevention in atrial fibrillation (AF), particularly into the use of novel oral anticoagulants (NOACs) for stroke prevention, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of NOACs for stroke prevention in AF. There were clear practice differences evident, and also the need for greater adherence to the guidelines, especially since guideline adherent management results in better outcomes in AF.
引用
收藏
页码：1526 / 1532
页数：7
相关论文
共 34 条
  • [1] Apostolakis S, 2013, CHEST, DOI [10.1378/chest.13-0054, DOI 10.1378/CHEST.13-0054]
  • [2] Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study
    Banerjee, Amitava
    Lane, Deirdre A.
    Torp-Pedersen, Christian
    Lip, Gregory Y. H.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) : 584 - 589
  • [3] Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
    Bin Abdulhak, Aref A.
    Khan, Abdur Rahman
    Tleyjeh, Imad M.
    Spertus, John A.
    Sanders, Susan U.
    Steigerwalt, Kristy E.
    Garbati, Musa A.
    Bahmaid, Reem A.
    Wimmer, Alan P.
    [J]. EUROPACE, 2013, 15 (10): : 1412 - 1420
  • [4] Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/eurheartj/ehs253, 10.1093/europace/eus305]
  • [5] Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
    Dans, Antonio L.
    Connolly, Stuart J.
    Wallentin, Lars
    Yang, Sean
    Nakamya, Juliet
    Brueckmann, Martina
    Ezekowitz, Michael
    Oldgren, Jonas
    Eikelboom, John W.
    Reilly, Paul A.
    Yusuf, Salim
    [J]. CIRCULATION, 2013, 127 (05) : 634 - 640
  • [6] Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
    Dewilde, Willem J. M.
    Oirbans, Tom
    Verheugt, Freek W. A.
    Kelder, Johannes C.
    De Smet, Bart J. G. L.
    Herrman, Jean-Paul
    Adriaenssens, Tom
    Vrolix, Mathias
    Heestermans, Antonius A. C. M.
    Vis, Marije M.
    Tijsen, Jan G. P.
    van 't Hof, Arnoud W.
    ten Berg, Jurrien M.
    [J]. LANCET, 2013, 381 (9872) : 1107 - 1115
  • [7] Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
    Eikelboom, John W.
    Wallentin, Lars
    Connolly, Stuart J.
    Ezekowitz, Mike
    Healey, Jeff S.
    Oldgren, Jonas
    Yang, Sean
    Alings, Marco
    Kaatz, Scott
    Hohnloser, Stefan H.
    Diener, Hans-Christoph
    Franzosi, Maria Grazia
    Huber, Kurt
    Reilly, Paul
    Varrone, Jeanne
    Yusuf, Salim
    [J]. CIRCULATION, 2011, 123 (21) : 2363 - U72
  • [8] Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting A North-American perspective
    Faxon, David P.
    Eikelboom, John W.
    Berger, Peter B.
    Holmes, David R.
    Bhatt, Deepak L.
    Moliterno, David J.
    Becker, Richard C.
    Angiolillo, Dominick J.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2011, 106 (04) : 572 - 584
  • [9] Fitzmaurice DA, 2005, BRIT MED J, V331, P1057, DOI 10.1136/bmj.38618.580903.AE
  • [10] Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study
    Friberg, Leif
    Rosenqvist, Marten
    Lip, Gregory Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (12) : 1500 - +
1234